Since MAPK (Ras-Raf-MEK-ERK) and p53 signaling pathways are closely related and jointly participate in regulating tumor treatment resistance, as described in many scientific publications [65,66,67], we explored the involvement of the p53 family proteins in the emergence of vemurafenib resistance. This evidence concerns the gene MAP2K7 and neoplasm.